Skip to main content
SpringerLink
Log in

The β2-Agonist Controversy

Observations, Explanations and Relationship to Asthma Epidemiology

  • Review Articles
  • Pharmacoepidemiology
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Links between frequent use of inhaled β2-agonists and morbidity and mortality from asthma appear probable. Two mortality epidemics followed the marketing of potent inhaled adrenergic agents. Case-control studies in New Zealand linked mortality with prescription of fenoterol, especially in severe asthma. A Saskatchewan case-control study confirmed an association of mortality with fenoterol, and also with frequent use of salbutamol (albuterol). Cardiac effects of β2-agonists do not cause mortality, but frequent use of these agents may increase the chronic severity of asthma, hence increasing the number of asthmatic patients at risk of death in an acute attack. Frequent use of β2-agonists may reduce lung function, increasing airway responsiveness, and impair control of asthma, despite use of inhaled corticosteroids. Mechanisms for this effect may include tachyphylaxis to nonbronchodilator effects, increased responsiveness to allergen, interaction with corticosteroid receptors, altered mucociliary function, differential effects of enantiomers, and masking of symptoms by β2-agonist use. The withdrawal of fenoterol from New Zealand in 1990 was associated with a substantial decline in morbidity and mortality.

Overall, the evidence suggests that frequent use of inhaled β2-agonists has a deleterious effect on the control of asthma. Epidemics of mortality are explained by an increase in chronic severity of asthma following introduction of more potent β2-agonists. While β2-agonists remain essential for relief of breakthrough symptoms, long term use, particularly with high doses of potent agents, appears to be detrimental.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Crane J, Pearce N, Flatt A, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet 1989; 1: 918–22

    Google Scholar 

  2. Spitzer WO, Suissa S, Ernst P, et al. The use of β-agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326: 501–6

    PubMed  CAS  Google Scholar 

  3. Pearce N, Crane J, Burgess C, et al. Beta agonists and asthma mortality: deja vu. Clin Exp Allergy 1991; 21: 401–10

    PubMed  CAS  Google Scholar 

  4. Sears MR, Taylor DR. Regular beta-agonist therapy — the quality of the evidence. Eur Respir J 1992; 5: 896–7

    PubMed  CAS  Google Scholar 

  5. Speizer FE, Doll R, Heaf P. Observations on recent increase in mortality from asthma. BMJ 1968; 1: 335–9

    PubMed  CAS  Google Scholar 

  6. Fraser PM, Speizer FE, Waters SDM, et al. The circumstances preceding death from asthma in young people in 1968 to 1969. Br J Dis Chest 1971; 65: 71–84

    PubMed  CAS  Google Scholar 

  7. Inman WHW, Adelstein AM. Rise and fall of asthma mortality in England and Wales in relation to use of pressurised aerosols. Lancet 1969; 2: 279–85

    PubMed  CAS  Google Scholar 

  8. Stolley PD, Schinnar R. Association between asthma mortality and isoproterenol aerosols: a review. Prev Med 1978; 7: 519–38

    PubMed  CAS  Google Scholar 

  9. Bradford Hill A. The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295–300

    Google Scholar 

  10. Skarpaas UK, Gulsvik A. Prevalence of bronchial asthma and respiratory symptoms in schoolchildren in Oslo. Allergy 1984; 40: 295–9

    Google Scholar 

  11. Asher MI, Pattemore PK, Harrison AC, et al. International comparison of the prevalence of asthma symptoms and bronchial hyperresponsiveness. Am Rev Respir Dis 1988; 138: 524–9

    PubMed  CAS  Google Scholar 

  12. Sears MR. Epidemiology. In: Barnes PJ, Rodger IW, Thomson NC, editors. Asthma: basic mechanisms and clinical management. London: Academic Press, 1992: 1–19

    Google Scholar 

  13. McWhorter WP, Polis MA, Kaslow RA. Occurrence, predictors, and consequences of adult asthma in NHANESI and follow-up survey. Am Rev Respir Dis 1989; 139: 721–4

    PubMed  CAS  Google Scholar 

  14. Woolcock AJ, Peat JK, Salome CM, et al. Prevalence of bronchial hyperresponsiveness and asthma in a rural adult population. Thorax 1987; 42: 361–8

    PubMed  CAS  Google Scholar 

  15. Jackson R, Sears MR, Beaglehole R, et al. International trends in asthma mortality: 1970 to 1985. Chest 1988; 94: 914–8

    PubMed  CAS  Google Scholar 

  16. Sly RM. Mortality from asthma, 1979–1984. J Allergy Clin Immunol 1988; 82: 705–17

    PubMed  CAS  Google Scholar 

  17. Wilson JD, Sutherland DC, Thomas AC. Has the change to beta-agonists combined with oral theophylline increased cases of fatal asthma? Lancet 1981; 1: 1235–7

    PubMed  CAS  Google Scholar 

  18. Sears MR, Rea HH, Beaglehole R, et al. Asthma mortality in New Zealand: a two year national study. NZ Med J 1985; 98: 271–5

    CAS  Google Scholar 

  19. Sears MR, Rea HH, de Boer G, et al. Accuracy of certification of deaths due to asthma: a national study. Am J Epidemiol 1986; 124: 1004–11

    PubMed  CAS  Google Scholar 

  20. Sears MR, Rea HH, Fenwick J, et al. 75 deaths in asthmatics prescribed home nebulisers. BMJ 1987; 294: 477–80

    PubMed  CAS  Google Scholar 

  21. Sears MR, Rea HH, Rothwell RPG, et al. Asthma mortality: comparison between New Zealand and England. BMJ 1986; 293: 1342–5

    PubMed  CAS  Google Scholar 

  22. Rea HH, Sears MR, Beaglehole R, et al. Lessons from the national asthma mortality study: circumstances surrounding death. NZ Med J 1987; 100: 10–3

    CAS  Google Scholar 

  23. Sears MR. The short- and long-term effects of ß2-agonists. In: Holgate ST, Austen KF, Lichtenstein LM, et al., editors. Asthma: physiology, immunopharmacology, and treatment. London: Academic Press, 1993; 359–74

    Google Scholar 

  24. Crane J, Burgess C, Pearce N, et al. Asthma deaths in New Zealand. BMJ 1992; 304: 1307

    PubMed  CAS  Google Scholar 

  25. Schenker MB, Goldf EB, Lopez RL, et al. Asthma mortality in California, 1960–1989. Am Rev Respir Dis 1993; 147: 1454–60

    PubMed  CAS  Google Scholar 

  26. Sears MR. Worldwide trends in asthma mortality. Bull Int Union Tuberc Lung Dis 1991; 66: 79–83

    PubMed  CAS  Google Scholar 

  27. BTA Subcommittee. Accuracy of death certificates in bronchial asthma. Thorax 1984; 39: 505–9

    Google Scholar 

  28. Weiss KB, Gergen PJ, Wagener DK. Breathing better or wheezing worse? The changing epidemiology of asthma morbidity and mortality. Annu Rev Public Health 1993; 14: 491–513

    PubMed  CAS  Google Scholar 

  29. Sears MR. Epidemiology of asthma. In: O’Byrne PM, editor. Asthma as an inflammatory disease. New York: Marcel Dekker, 1990; 15–48

    Google Scholar 

  30. Mao Y, Semenciw R, Morrison H, et al. Increased rates of illness and death from asthma in Canada. Can Med Assoc J 1987; 137: 620–4

    CAS  Google Scholar 

  31. Weiss KB, Wagener DK. Geographic variations in US asthma mortality: small-area analyses of excess mortality, 1981–1985. Am J Epidemiol 1990; 132 Suppl. 1: S107–15

    PubMed  CAS  Google Scholar 

  32. Kaplan KM. Epidemiology of deaths from asthma in Pennsylvania, 1978-87. Public Health Rep 1993; 108: 66–9

    PubMed  CAS  Google Scholar 

  33. Carr W, Zeitel L, Weiss K. Variations in asthma hospitalizations and deaths in New York City. Am J Public Health 1992; 82: 59–65

    PubMed  CAS  Google Scholar 

  34. Marder D, Targonski P, Orris P, et al. Effect of racial and socioeconomic factors on asthma mortality in Chicago. Chest 1992; 101: 426–9

    Google Scholar 

  35. Speight ANP, Lee DA, Hey EN. Underdiagnosis and undertreatment of asthma in childhood. BMJ 1983; 286: 1253–6

    PubMed  CAS  Google Scholar 

  36. Barnes PJ. Anti-inflammatory therapy for asthma. Ann Rev Med 1993; 44: 229–42

    PubMed  CAS  Google Scholar 

  37. Laitinen LA, Laitinen A, Heino M, et al. Eosinophilic airway inflammation during exacerbation of asthma and its treatment with inhaled corticosteroid. Am Rev Respir Dis 1991; 143: 423–7

    PubMed  CAS  Google Scholar 

  38. Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Am Rev Respir Dis 1993; 148: S1–26

    PubMed  CAS  Google Scholar 

  39. Paterson JW, Woolcock AJ, Shenfield GM. Bronchodilator drugs. Am Rev Respir Dis 1979; 120: 1149–88

    PubMed  CAS  Google Scholar 

  40. Price AH, Clissold SP. Salbutamol in the 1980s. A reappraisal of its clinical efficacy. Drugs 1989; 38: 77–122

    PubMed  CAS  Google Scholar 

  41. Keating G, Mitchell EA, Jackson R, et al. Trends in sales of drugs for asthma in New Zealand, Australia and the United Kingdom 1975-81. BMJ 1984; 289: 348–51

    PubMed  CAS  Google Scholar 

  42. Bosco LA, Knapp DE, Gerstman B, et al. Asthma drug therapy in the United States, 1972 to 1985. J Allergy Clin Immunol 1987; 80: 398–402

    PubMed  CAS  Google Scholar 

  43. British Thoracic Association. Death from asthma in two regions of England. BMJ 1982; 285: 1251–4

    Google Scholar 

  44. Johnson AJ, Nunn AJ, Somner AR, et al. Circumstances of death from asthma. BMJ 1984; 288: 1870–2

    PubMed  CAS  Google Scholar 

  45. Wilson JD. Selective prescribing of fenoterol and salbutamol in New Zealand general practice. Post Marketing Surveillance 1991; 5: 105–18

    CAS  Google Scholar 

  46. Petri H, Urquhart J, Herings R, et al. Characteristics of patients prescribed three different inhalation beta2 agonists: an example of the channeling phenomenon. Post Marketing Surveillance 1991; 5: 57–66

    Google Scholar 

  47. Beasley R, Crane J, Burgess C, et al. Fenoterol and severe asthma mortality. NZ Med J 1989; 102: 294–6

    Google Scholar 

  48. Committee on Safety of Medicines. Beta agonist use in asthma: report from the CSM Working Party. London: CSM, 1992: Report no. 33

    Google Scholar 

  49. Costello J. Asthma — the problem and the paradox. Postgrad Med J 1991; 67 Suppl. 4: S1–5

    PubMed  Google Scholar 

  50. Taylor DR, Sears MR. Debate in print. Regular inhaled ß-agonists — evidence, not reassurance, is what is needed. Chest 1994; 106: 552–9

    PubMed  CAS  Google Scholar 

  51. Rea HH, Scragg R, Jackson R, et al. A case-control study of deaths from asthma. Thorax 1986; 41: 833–9

    PubMed  CAS  Google Scholar 

  52. O’Donnell TV, Rea HH, Holst PE, et al. Fenoterol and fatal asthma. Lancet 1989; 1: 1070–1

    Google Scholar 

  53. Buist AS, Burney PGJ, Feinstein AR, et al. Fenoterol and fatal asthma. Lancet 1989; 1: 1071

    Google Scholar 

  54. Poole C, Lanes SF, Walker AM. Fenoterol and fatal asthma. Lancet 1990; 335: 920

    PubMed  CAS  Google Scholar 

  55. Sackett DL, Shannon HS, Browman GW. Fenoterol and fatal asthma. Lancet 1990; 335: 45–6

    PubMed  CAS  Google Scholar 

  56. Pearce N, Grainger J, Atkinson M, et al. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. Thorax 1990; 45: 170–5

    PubMed  CAS  Google Scholar 

  57. Grainger J, Woodman K, Pearce N, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study. Thorax 1991; 46: 105–11

    PubMed  CAS  Google Scholar 

  58. Horwitz RI, Spitzer W, Buist S, et al. Clinical complexity and epidemiologic uncertainty in case-control research. Fenoterol and asthma management. Chest 1991; 100: 1586–91

    PubMed  CAS  Google Scholar 

  59. Paterson JW, Conolly ME, Davies DS, et al. Isoprenaline resistance and the use of pressurised aerosols in asthma. Lancet 1968; 2: 426–9

    PubMed  CAS  Google Scholar 

  60. Lipworth BJ, Struthers AD, McDevitt DG. Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics. Am Rev Respir Dis 1989; 140: 586–92

    PubMed  CAS  Google Scholar 

  61. Lehr D. Isoproterenol and sudden death of asthmatic patients in ventricular fibrillation. N Engl J Med 1972; 287: 987–8

    PubMed  CAS  Google Scholar 

  62. Al-Hillawi AH, Hayward R, Johnson NM. Incidence of cardiac arrhythmias in patients taking slow release salbutamol and slow release terbutaline for asthma. BMJ 1984; 288: 367

    PubMed  CAS  Google Scholar 

  63. Lipworth BJ. Risks versus benefits of inhaled β2-agonists in the management of asthma. Drug Saf 1992; 7: 54–70

    PubMed  CAS  Google Scholar 

  64. Haalboom JRE, Deenstra M, Struyvenberg A. Hypokalaemia induced by inhalation of fenoterol. Lancet 1985; 1: 1125–7

    PubMed  CAS  Google Scholar 

  65. Scheinin M, Koulu M, Laurikainen E, et al. Hypokalaemia and other non-bronchial effects of inhaled fenoterol and salbutamol: a placebo-controlled dose-response study in healthy volunteers. Br J Clin Pharmacol 1987; 24: 645–53

    PubMed  CAS  Google Scholar 

  66. Kelly WH, Menendez R, Voyles W. Lack of significant arrhythmogenicity from chronic theophylline and beta-2-adrenergic combination therapy in asthmatic subjects. Ann Allergy 1985; 54: 405–10

    PubMed  CAS  Google Scholar 

  67. Taylor GJ, Harris WS. Cardiac toxicity of aerosol propellants. JAMA 1970; 214: 81–5

    PubMed  CAS  Google Scholar 

  68. Sly RM. Adverse effects and complications of treatment with beta-adrenergic agonist drugs. J Allergy Clin Immunol 1985; 75: 443–9

    Google Scholar 

  69. Belej MA, Aviado DM. Cardiopulmonary toxicity of propellants for aerosols. J Clin Pharmacol 1975; 15: 105–15

    PubMed  CAS  Google Scholar 

  70. Aviado DM. Toxicity of aerosols. J Clin Pharmacol 1975; 15: 86–104

    PubMed  CAS  Google Scholar 

  71. Molfino NA, Nannini LJ, Martelli AN, et al. Respiratory arrest in near-fatal asthma. N Engl J Med 1991; 324: 285–8

    PubMed  CAS  Google Scholar 

  72. Crane J, Burgess C, Beasley R. Cardiovascular and hypokalaemic effects of inhaled salbutamol, fenoterol, and isoprenaline. Thorax 1989; 44: 136–40

    PubMed  CAS  Google Scholar 

  73. Smyth ET, Pavord ID, Wong CS, et al. Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma. BMJ 1993; 306: 543–5

    PubMed  CAS  Google Scholar 

  74. Guideri G, Barletta MA, Lehr D. Extraordinary potentiation of isoproterenol cardiotoxicity by corticoid pretreatment. Cardiovasc Res 1974; 8: 775–86

    PubMed  CAS  Google Scholar 

  75. Taylor DR, Wilkins GT, Herbison GP, et al. Interaction between corticosteroid and β-agonist drugs: biochemical and cardiovascular effects in normal subjects. Chest 1992; 102: 519–24

    PubMed  CAS  Google Scholar 

  76. Bonnin AJ, Richmond GW, Musto PK, et al. Repeated inhalation of nebulized albuterol did not induced arrhythmias in a patient with Wolff-Parkison-White syndrome and asthma. Chest 1993; 103: 1892–4

    PubMed  CAS  Google Scholar 

  77. Seider N, Abinader EG, Oliven A. Cardiac arrhythmias after inhaled bronchodilators in patients with COPD and ischaemic heart disease. Chest 1993; 104: 1070–4

    PubMed  CAS  Google Scholar 

  78. Ziment I. Infrequent cardiac deaths occur in bronchial asthma. Chest 1992; 101: 1703–5

    PubMed  CAS  Google Scholar 

  79. Robin ED, McCauley R. Sudden cardiac death in bronchial asthma, and inhaled beta-adrenergic agonists. Chest 1992; 101: 1699–702

    PubMed  CAS  Google Scholar 

  80. Miller BD, Strunk RC. Circumstances surrounding the deaths of children due to asthma. A case-control study. Am J Dis Child 1989; 143: 1294–9

    PubMed  CAS  Google Scholar 

  81. Bremner P, Burgess CD, Crane J, et al. Cardiovascular effects of fenoterol under conditions of hypoxaemia. Thorax 1992; 47: 814–7

    PubMed  CAS  Google Scholar 

  82. Anderson HR. Increase in hospital admissions for childhood asthma: trends in referral, severity, and readmissions from 1970 to 1985 in a health region of the United Kingdom. Thorax 1989; 44: 614–9

    PubMed  CAS  Google Scholar 

  83. Evans R III, Mullally DI, Wilson RW, et al. National trends in the morbidity and mortality of asthma in the US. Prevalence, hospitalization and death from asthma over two decades: 1965–1984. Chest 1987; 91: 65S–74S

    PubMed  Google Scholar 

  84. Dawson KP. The severity of asthma in children admitted to hospital: a 20 year review. NZ Med J 1987; 100: 520–1

    CAS  Google Scholar 

  85. Rea H, Sears M, Mitchell E, et al. Is asthma becoming more severe? Thorax 1987; 42: 736

    Google Scholar 

  86. US Department of Health and Human Services, National Institutes of Health. International consensus report on diagnosis and management of asthma. NIH Publication no. 92-3091, June 1992

  87. Van As A. Beta-adrenergic stimulant bronchodilators. In: Stein M, editor. New directions in asthma. Lund: American College of Chest Physicians, printed by Rahms 1974; 415–32

    Google Scholar 

  88. Vanderwalker ML, Kray KT, Weber RW, et al. Addition to terbutaline to optimal theophylline therapy. Double blind crossover study in asthmatic patients. Chest 1986; 90: 198–203

    Google Scholar 

  89. Smith JA, Weber RW, Nelson HS. Theophylline and aerosolized terbutaline in the treatment of bronchial asthma. Double-blind comparison of optimal doses. Chest 1980; 78: 816–8

    PubMed  CAS  Google Scholar 

  90. Bennati D, Piacentini GL, Peroni DG, et al. Changes in bronchial reactivity in asthmatic children after treatment with beclomethasone alone or in association with salbutamol. J Asthma 1989; 26: 359–64

    PubMed  CAS  Google Scholar 

  91. Horn CR, Clark TJH, Cochrane GM. Inhaled therapy reduces morning dips in asthma. Lancet 1984; 1: 1143–5

    PubMed  CAS  Google Scholar 

  92. Haahtela T, Alanko K, Muittari A, et al. The superiority of combination beclomethasone and salbutamol over standard dosing of salbutamol in the treatment of chronic asthma. Ann Allergy 1989; 62: 63–6

    PubMed  CAS  Google Scholar 

  93. Prior JG, Nowell RV, Cochrane GM. High-dose inhaled terbutaline in the management of chronic severe asthma: comparison of wet nebulisation and tube-spacer delivery. Thorax 1992; 37: 300–3

    Google Scholar 

  94. O’Driscoll BRC, Ruffles SP, Ayres JG, et al. Long term treatment of severe asthma with subcutaneous terbutaline. Br J Dis Chest 1988; 82: 360–7

    PubMed  Google Scholar 

  95. Cluzel M, Bousquet J, Daures JP, et al. Ambulatory long-term subcutaneous salbutamol infusion in chronic severe asthma. J Allergy Clin Immunol 1990; 85: 599–605

    PubMed  CAS  Google Scholar 

  96. Horn CR, Clark TJH, Cochrane GM. Can the morbidity of asthma be reduced by high dose inhaled therapy? A prospective study. Respir Med 1990; 84: 61–6

    PubMed  CAS  Google Scholar 

  97. Van Schayck CP, Dompeling E, Van Herwaarden CLA, et al. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study. BMJ 1991; 303: 1426–31

    PubMed  Google Scholar 

  98. Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild to moderate asthma. N Engl J Med 1992; 327: 1420–5

    PubMed  CAS  Google Scholar 

  99. Haahtela T, Ahokas I, Ahonen A, et al. Inhaled bronchodilators in asthma: low or high dose? Ann Allergy 1991; 66: 175–80

    PubMed  CAS  Google Scholar 

  100. Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990; 336: 1391–6

    PubMed  CAS  Google Scholar 

  101. Taylor DR, Sears MR, Herbison GP, et al. Regular inhaled beta-agonist: effects on lung function and exacerbations. Thorax 1993; 48: 134–8

    PubMed  CAS  Google Scholar 

  102. Nelson HS, Szefler SJ, Martin RJ. Regular inhaled beta-adrenergic agonists in the treatment of bronchial asthma: beneficial or detrimental? Am Rev Respir Dis 1991; 144: 249–50

    PubMed  CAS  Google Scholar 

  103. Lofdahl C-G, Svedmyr N. Beta-agonists — friends or foes? Eur Respir J 1991; 4: 1161–5

    PubMed  CAS  Google Scholar 

  104. Cochrane GM. Regular versus intermittent inhaled bronchodilator therapy in the treatment of asthma. Res Clin Forums 1984; 6: 55–9

    Google Scholar 

  105. Shepherd GL, Hetzel MR, Clark TJH. Regular versus symptomatic aerosol bronchodilator treatment of asthma. Br J Dis Chest 1981; 75: 215–7

    PubMed  CAS  Google Scholar 

  106. Zellweger JP, Clottu R, Crittin A, et al. Etude comparee des effets de l’inhalation de salbutamol regulierement ou a la demande dans le traitement de l’asthme. Schweiz Med Wochenschr 1986; 116: 1260–3

    PubMed  CAS  Google Scholar 

  107. Wahedna I, Wong CS, Wisniewski AFZ, et al. Asthma control during and after cessation of regular beta2 agonist treatment. Am Rev Respir Dis 1993; 148: 707–12

    PubMed  CAS  Google Scholar 

  108. Trembath PW, Greenacre JK, Anderson M, et al. Comparison of four weeks’ treatment with fenoterol and terbutaline aerosols in adult asthmatics. J Allergy Clin Immunol 1979; 63: 395–400

    PubMed  CAS  Google Scholar 

  109. Patakas D, Maniki E, Tsara V, et al. Intermittent and continuous salbutamol rotacaps inhalation in asthmatic patients. Respiration 1988; 54: 174–8

    PubMed  CAS  Google Scholar 

  110. Van Arsdel Jr PP, Schaffrin RM, Rosenblatt J, et al. Evaluation of oral fenoterol in chronic asthmatic patients. Chest 1978; 73 Suppl.: 997–8

    Google Scholar 

  111. Van Schayck CP, Van Herwaarden CLA. Do bronchodilators adversely affect the prognosis of bronchial hyperresponsiveness? Thorax 1993; 48: 470–3

    PubMed  Google Scholar 

  112. Taylor DR, Sears MR. Bronchodilators and bronchial hyperresponsiveness. Thorax 1994; 49: 190

    PubMed  CAS  Google Scholar 

  113. Vathenen AS, Higgins BG, Knox AJ, et al. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet 1988; 1: 554–8

    PubMed  CAS  Google Scholar 

  114. Van Schayck CP, Graafsma SJ, Visch MB, et al. Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol. J Allergy Clin Immunol 1990; 86: 793–800

    PubMed  Google Scholar 

  115. Kraan J, Koeter GH, v d Mark ThW, et al. Changes in bronchia hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J Allergy Clin Immunol 1985; 76: 628–36

    PubMed  CAS  Google Scholar 

  116. Raes M, Mulder P, Kerrebijn KF. Long-term effect of ipratropium bromide and fenoterol on the bronchial hyperresponsiveness to histamine in children with asthma. J Allergy Clin Immunol 1989; 84: 874–9

    PubMed  CAS  Google Scholar 

  117. Town I, O’Donnell TV, Purdie G. Bronchial responsiveness during regular fenoterol therapy: a 4 months prospective study. NZ Med J 1991; 104: 3–5

    CAS  Google Scholar 

  118. Kerrebijn KF, van Essen-Zandvliet EEM, Neijens HJ. Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol 1987; 79: 653–9

    PubMed  CAS  Google Scholar 

  119. Haahtela T, Jarvinen M, Kava T, et al. Comparison of β2-ago-nist, terbutaline with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991; 325: 388–92

    PubMed  CAS  Google Scholar 

  120. Kerstjens HAM, Brand PLP, Hughes MD, et al. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. N Engl J Med 1992; 327: 1413–9

    PubMed  CAS  Google Scholar 

  121. Peel ET, Gibson GJ. Effects of long-term inhaled salbutamol therapy on the provocation of asthma by histamine. Am Rev Respir Dis 1980; 121: 973–8

    PubMed  CAS  Google Scholar 

  122. Mitchell EA. Is current treatment increasing asthma mortality and morbidity? Thorax 1989; 44: 81–4

    PubMed  CAS  Google Scholar 

  123. Van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, et al. Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. Am Rev Respir Dis 1992; 146: 547–54

    PubMed  Google Scholar 

  124. Hargreave FE, Ryan G, Thomson NC, et al. Bronchial responsiveness to histamine or methacholine in asthma: measurement and clinical significance. J Allergy Clin Immunol 1981; 68: 347–55

    PubMed  CAS  Google Scholar 

  125. Cutrera R, Filtchev SI, Merolla R, et al. Analysis of expiratory pattern for monitoring bronchial obstruction in school-age children. Pediatr Pulmonol 1991; 10: 6–10

    PubMed  CAS  Google Scholar 

  126. Conolly ME, Davies DS, Dollery CT, et al. Resistance to β-ad-renoeptor stimulants (a possible explanation for the rise in asthma deaths). Br J Pharmacol 1971; 43: 389–402

    PubMed  CAS  Google Scholar 

  127. Conolly ME, Greenacre JK. The lymphocyte β-adrenoceptor in normal subjects and patients with bronchial asthma. J Clin Invest 1976; 58: 1307–16

    PubMed  CAS  Google Scholar 

  128. Galant SP, Duriseti L, Underwood S, et al. Decreased betaadrenergic receptors on polymorphonuclear leucocytes after adrenergic therapy. N Engl J Med 1978; 299: 933–6

    PubMed  CAS  Google Scholar 

  129. Harvey JE, Baldwin CJ, Wood PJ, et al. Airway and metabolic responsiveness to intravenous salbutamol in asthma: effect of regular inhaled salbutamol. Clin Sci 1981; 60: 579–85

    PubMed  CAS  Google Scholar 

  130. Lipworth BJ, Clark RA, Dhillon DP, et al. Comparison of the effects of prolonged treatment with low and high doses of inhaled terbutaline on beta-adrenoceptor responsiveness in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1990; 142: 338–42

    PubMed  CAS  Google Scholar 

  131. Harvey JE, Tattersfield AE. Airway response to salbutamol: effect of regular salbutamol inhalations in normal, atopic and asthmatic subjects. Thorax 1982; 37: 280–7

    PubMed  CAS  Google Scholar 

  132. Tashkin DP, Conolly ME, Deutsch RI, et al. Subsensitization of beta-adrenoceptors in airways and lymphocytes of healthy and asthmatic subjects. Am Rev Respir Dis 1982; 125: 185–93

    PubMed  CAS  Google Scholar 

  133. Nelson HS, Raine D, Doner CH, et al. Subsensitivity to the bronchodilator action of albuterol produced by chronic administration. Am Rev Respir Dis 1988; 16: 871–8

    Google Scholar 

  134. Jenne JW, Chick TW, Strickland RD, et al. Subsensitivity of beta responses during therapy with a long-acting beta-2 preparation. J Allergy Clin Immunol 1977; 49: 383–90

    Google Scholar 

  135. Weber RW, Smith JA, Nelson HS. Aerosolized terbutaline in asthmatics: development of subsensitivity with long-term administration. J Allergy Clin Immunol 1982; 70: 417–22

    PubMed  CAS  Google Scholar 

  136. Larsson K, Martinsson A, Hjemdahl P. Influence of β-adrenergic receptor function during terbutaline treatment on allergen sensitivity and bronchodilator response to terbutaline in asthmatic subjects. Chest 1992; 101: 953–60

    PubMed  CAS  Google Scholar 

  137. Svedmyr N, Larsson S, Thiringer G. Studies of resistance to long-acting adrenergic beta-stimulators in asthmatic patients. BMJ 1974; 2: 668–9

    PubMed  CAS  Google Scholar 

  138. Larsson S, Svedmyr N, Thiringer G. Lack of bronchial beta adrenoceptor resistance in asthmatics during long term treatment with terbutaline. J Allergy Clin Immunol 1977; 59: 93–100

    PubMed  CAS  Google Scholar 

  139. Repsher LH, Anderson JA, Bush RK, et al. Assessment of tachyphylaxis following prolonged therapy of asthma with inhaled albuterol aerosol. Chest 1984; 85: 34–8

    PubMed  CAS  Google Scholar 

  140. Hauck RW, Böhm M, Gengenbach S, et al. ß2-adrenoceptors in human and peripheral mononuclear lymphocytes of untreated and terbutaline treated patients. Chest 1990; 98: 376–81

    PubMed  CAS  Google Scholar 

  141. Gibson GJ, Greenacre JK, Konig P, et al. Use of exercise challenge to investigate possible tolerance to beta-adrenoceptor stimulation in asthma. Br J Dis Chest 1978; 72: 199–206

    PubMed  CAS  Google Scholar 

  142. O’Connor BJ, Aikman SL, Barnes PJ. Tolerance to the non-bronchodilator effects of inhaled ß2-agonists in asthma. N Engl J Med 1992; 327: 1204–8

    PubMed  Google Scholar 

  143. Bel EH, Zwinderman AH, Timmers MC, et al. The protective effect of a beta2 agonist against excessive airway narrowing in the response to bronchoconstrictor stimuli in asthma and chronic obstructive lung disease. Thorax 1991; 46: 9–14

    PubMed  CAS  Google Scholar 

  144. Wong CS, Wahedna I, Pavord ID, et al. The effect of regular terbutaline and budesonide on bronchial reactivity to allergen challenge. Am J Respir Crit Care Med. In press

  145. Cockcroft DW, McParland CP, Britto SA, et al. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 1993; 342: 833–7

    PubMed  CAS  Google Scholar 

  146. Swystun V, Bhagat R, O’Byrne PM, et al. Regular inhaled salbutamol increases allergen-induced late asthmatic responsiveness. J Allergy Clin Immunol 1994; 93: 260

    Google Scholar 

  147. Morley J, Sanjar S, Newth C. Viewpoint: untoward effects of beta-adrenoceptor agonists in asthma. Eur Respir J 1990; 3: 226–33

    Google Scholar 

  148. Lai CKW, Twentyman OP, Holgate ST. The effect of an increase in inhaled allergen dose after rimiterol hydrobromide on the occurrence and magnitude of the late asthmatic response and the associated change in nonspecific bronchial responsiveness. Am Rev Respir Dis 1989; 140: 917–23

    PubMed  CAS  Google Scholar 

  149. O’Hollaren MT, Yunginger JW, Offord KP, et al. Exposure to an aeroallergen as a possible precipitating factor in respiratory arrest in young patients with asthma. N Engl J Med 1991; 324: 359–63

    PubMed  Google Scholar 

  150. Svedmyr N. Action of corticosteroids on beta-adrenergic receptors: clinicals aspects. Am Rev Respir Dis 1990; 141: S31–8

    PubMed  CAS  Google Scholar 

  151. Ihara I, Nakanishi S. Selective inhibition of expression of substance P receptor mRNA in pancreatic acinar AR42J cells by glucocorticoids. J Biol Chem 1990; 26: 22441–5

    Google Scholar 

  152. Schule R, Rangarajan P, Kliewer S, et al. Functional antagonism between oncoprotein c-JUN and the glucocorticoid receptor. Cell 1990; 62: 1217–26

    PubMed  CAS  Google Scholar 

  153. Peters MJ, Adcock IM, Brown CR, et al. β-agonist inhibition of steroid-receptor DNA binding activity in human lung [abstract]. Am Rev Respir Dis 1993; 147: A772

    Google Scholar 

  154. Waalkens HJ, Gerritsen J, Koeter GH, et al. Budesonide and terbutaline or terbutaline alone in children with mild asthma: effects on bronchial hyperresponsiveness and diurnal variation in peak flow. Thorax 1991; 46: 499–503

    PubMed  CAS  Google Scholar 

  155. Selroos GO, Nyholm JE. Infuence of a budesonide-terbutaline combination on bronchial hyper-reactivity. Clin Exp Allergy 1990; 20 Suppl. 1: 76

    Google Scholar 

  156. Cochrane GM, Horn CR. The management of asthma in the community: problems of compliance with treatment. Q J Med 1991; 294: 797–8

    Google Scholar 

  157. Arvidsson P, Larsson S, Lofdahl C-G, et al. Inhaled formoterol during one year in asthma: a comparison with salbutamol. Eur Respir J 1991; 4: 1168–73

    PubMed  CAS  Google Scholar 

  158. Messina MS, O’Riordan TG, Smaldone GC. Changes in mucociliary clearance during acute exacerbations of asthma. Am Rev Respir Dis 1991; 143: 993–7

    PubMed  CAS  Google Scholar 

  159. Bateman JRM, Pavia D, Shehan NF, et al. Impaired mucociliary clearance in patients with mild stable asthma. Thorax 1984; 38: 463–7

    Google Scholar 

  160. Pavia D, Bateman JRM, Sheahan NF, et al. Tracheobronchial mucociliary clearance in asthma: impairment during remission. Thorax 1985; 40: 171–5

    PubMed  CAS  Google Scholar 

  161. Dunnill MS. Pathological changes in the airways in asthma. J Clin Pathol 1960; 13: 27–33

    PubMed  CAS  Google Scholar 

  162. Iravani J, Melville GN. Mucociliary function of the respiratory tract as influenced by drugs. Respiration 1974; 31: 350–7

    PubMed  CAS  Google Scholar 

  163. Foster WM, Bergofsky E, Bohning DE, et al. Effect of adrenergic agents and their mode of action on mucociliary clearance. J Appl Physiol 1976; 41: 146–52

    PubMed  CAS  Google Scholar 

  164. Kean WF, Lock CJL, Howard-Lock HE. Chirality in antirheumatic drugs. Lancet 1991; 338: 1565–8

    PubMed  CAS  Google Scholar 

  165. Sanjar S, Kristersson A, Mazzoni L, et al. Increased airway reactivity in the guinea-pig follows exposure to intravenous isoprenaline. J Physiol 1909; 425: 43–54

    Google Scholar 

  166. Galland BC, Blackman JG. Enhancement of airway reactivity to histamine by isoprenaline and related β-adrenoceptor agonists in the guinea pig. Br J Pharmacol 1993; 108: 1016–23

    PubMed  CAS  Google Scholar 

  167. Hartley D, Middlemiss D. Absolute configuration of the optical isomers of salbutamol. J Med Chem 1971; 14: 895–6

    CAS  Google Scholar 

  168. Brittain RT, Farmer JB, Marshall RJ. Some observations on the β-adrenoceptor agonist properties of the isomers of salbutamol. Br J Pharmacol 1973; 48: 144–7

    PubMed  CAS  Google Scholar 

  169. Hawkins CJ, Klease GT. Relative potency of (−) and (±) salbutamol on guinea pig trachéal tissue. J Med Chem 1973; 16: 856–7

    PubMed  CAS  Google Scholar 

  170. Tan YK, Soldin SJ. Analysis of salbutamol enantiomers in human urine by chiral high performance liquid chromatography and preliminary studies related to the stereoselective disposition kinetics in man. J Chromatogr 1987; 422: 187–96

    PubMed  CAS  Google Scholar 

  171. Keighley JF. Iatrogenic asthma associated with adrenergic aerosols. Ann Intern Med 1966; 65: 985–95

    PubMed  CAS  Google Scholar 

  172. Eisenstadt WS, Nicholas SS. The adverse effect of adrenergic aerosols in bronchial asthma. Ann Allergy 1969; 27: 283–8

    PubMed  CAS  Google Scholar 

  173. Reisman RE. Asthma induced by adrenergic aerosols. J Allergy 1970; 46: 162–77

    PubMed  CAS  Google Scholar 

  174. Trautlein J, Allegra J, Field J, et al. Paradoxic bronchospasm after inhalation of isoproterenol. Chest 1976; 70: 711–4

    PubMed  CAS  Google Scholar 

  175. Hansel TT, Schwarz F, Villiger B, et al. Anomolous bronchospasm following inhalation of (+) isoprenaline by asthmatics. New Drugs Allergy Asthma 1993; 281-8

  176. Suissa S, Ernst P, Spitzer WO. Asthma deaths in New Zealand. BMJ 1992; 305: 889

    PubMed  CAS  Google Scholar 

  177. Garrett JE, Kolbe J, Richards GN, et al. Asthma in New Zealand: trends in drug treatment, hospital admission and mortality rates, 1981–1991 [abstract]. Am Rev Respir Dis 1993; 147: A798

    Google Scholar 

  178. Benson RL, Perlman F. Clinical effects of epinephrine by inhalation. J Allergy 1948; 19: 129–40

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Firestone Regional Chest and Allergy Unit, St Joseph’s Hospital and McMaster University, 50 Charlton Avenue East, Hamilton, Ontario, L8N 4A6, Canada

    Malcolm R. Sears

  2. University of Otago Medical School, Dunedin, New Zealand

    D. Robin Taylor

Authors
  1. Malcolm R. Sears
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Robin Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sears, M.R., Taylor, D.R. The β2-Agonist Controversy. Drug-Safety 11, 259–283 (1994). https://doi.org/10.2165/00002018-199411040-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199411040-00005

Keywords

Search

Navigation